The FDA has approved Lumipulse, the first blood test for diagnosing Alzheimer’s, offering a simpler and less invasive option compared to traditional methods like PET scans. Experts believe this could revolutionize care and research.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
A new NIH-funded study reveals crucial protein changes in spinal fluid that may provide the first specific biomarkers for frontotemporal dementia (FTD), paving the way for earlier diagnosis and treatment options.
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
New research reveals that HIV drugs known as NRTIs can reduce the risk of developing Alzheimer’s disease by 6% to 13% annually. Scientists urge for clinical trials to explore this promising link.
Mike Hazen, GM of the Diamondbacks, shares his personal battle with glioblastoma and the impact of the Nicole Hazen Fund for Hope during the upcoming 'Brain Tumor Awareness Night' at Chase Field. Discover how this initiative supports crucial research and helps families affected by brain cancer.
Groundbreaking research suggests that the shingles vaccine may not only prevent shingles but also significantly lower the risk of dementia in older adults. A study analyzing health records shows compelling evidence supporting this connection.
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
A recent survey reveals that older Americans are increasingly proactive about Alzheimer's, with 79% wanting to know if they have the disease before symptoms arise. Many would opt for a blood test and are open to new drug treatments.
